Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 1
Submit an article Journal homepage
2,301
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy

Joanna BlockaDepartment of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany; Correspondence[email protected]
,
Thomas HielscherDepartment of Biostatistics, German Cancer Research Center, Heidelberg, Germany;
,
Carsten Mueller-TidowDepartment of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany;
,
Hartmut GoldschmidtDepartment of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany; ;National Center for Tumor Diseases, Heidelberg, Germany;
&
Jens HillengassDepartment of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany; ;Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Pages 27-36 | Received 03 Feb 2019, Accepted 13 Jul 2019, Published online: 19 Aug 2019

References

  • McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822–824.
  • Barlogie B, Hall R, Zander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67:1298–1301.
  • van de Velde HJ, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399–1406.
  • Alexanian R, Dimopoulos MA, Hester J, et al. Early myeloablative therapy for multiple myeloma. Blood. 1994;84:4278–4282.
  • Singhal S, Powles R, Sirohi B, et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Tr. 2002;30:673–679.
  • Kumar S, Lacy MQ, Dispenzieri A, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Tr. 2004;34:161–167.
  • Moreau P, Attal M, Pegourie B, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2011;117:3041–3044.
  • Rosinol L, Garcia-Sanz R, Lahuerta JJ, et al. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica 2012;97:616–621.
  • Parrish C, Rahemtulla A, Cavet J, et al. Autologous stem cell transplantation is an effective salvage therapy for primary refractory multiple myeloma. Biol Blood Marrow Tr. 2015;21:1330–1334.
  • Vij R, Kumar S, Zhang MJ, et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Tr. 2015;21:335–341.
  • Goldschmidt H, Sonneveld P, Cremer FW, et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol. 2003;82:654–659.
  • Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia 2018;32:383–390.
  • Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115–1123.
  • van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67.
  • r-project.org [Internet]. The R Project for Statistical Computing. [cited 2019 Feb 3]. Available from https://www.r-project.org/
  • Yoshida T, Ri M, Kinoshita S, et al. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma. PloS One. 2018;13:e0196780.
  • Selby PJ, McElwain TJ, Nandi AC, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol. 1987;66:55–62.
  • Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–97.
  • Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883.
  • Jackson GH, Davies FE, Pawlyn C, et al. Response adapted induction treatment improves outcomes for myeloma patients; results of the phase III myeloma XI study. Blood 2016;128:244–244.
  • Pawlyn C, Davies FE, Kaiser MF, et al. Primary IMiD refractory myeloma; results from 3894 patients treated in the phase III myeloma XI study. Blood 2016;128:1144–1144.
  • Paul B, Lipe B, Ocio EM, et al. Induction therapy for newly diagnosed multiple myeloma. Am Soc Clin Oncol Educ Book. 2019;39:e176–e186.
  • Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127:2955–2962.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.